Neuroinflammation is a major contributor to intracerebral hemorrhage (ICH) progression, but no drug is currently available to reduce this response and protect against ICH-induced injury. Recently, the natural product pinocembrin has been shown to ameliorate neuroinflammation and is undergoing a phase II clinical trial for ischemic stroke treatment. In this study, we examined the efficacy of pinocembrin in an ICH model, and further examined its effect on microglial activation and polarization. In vivo, pinocembrin dose-dependently reduced lesion volume by $47.5% and reduced neurologic deficits of mice at 72 h after collagenase-induced ICH. The optimal dose of pinocembrin (5 mg/kg) suppressed microglial activation as evidenced by decreases in CD68-positive microglia and reduced proinflammatory cytokines tumor necrosis factor (TNF)-a, interleukin (IL)-1b, and IL-6. Pinocembrin also reduced the number of classically activated M1-like microglia without affecting M2-like microglia in the perilesional region. Additionally, pinocembrin decreased the expression of toll-like receptor (TLR)4 and its downstream target proteins TRIF and MyD88. The protection by pinocembrin was lost in microglia-depleted mice and in TLR4 lps-del mice, and pinocembrin failed to decrease the number of M1-like microglia in TLR4 lps-del mice. In lipopolysaccharide-stimulated BV-2 cells or primary microglia, pinocembrin decreased M1-related cytokines and markers (IL-1b, IL-6, TNF-a, and iNOS), NF-jB activation, and TLR4 expression, but it did not interfere with TLR4/MyD88 and TLR4/TRIF interactions or affect microglial phagocytosis of red blood cells. Inhibition of the TLR4 signaling pathway and reduction in M1-like microglial polarization might be the major mechanism by which pinocembrin protects hemorrhagic brain. With anti-inflammatory properties, pinocembrin could be a promising new drug candidate for treating ICH and other acute brain injuries.
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Introduction
Intracerebral hemorrhage (ICH) is a significant cause of morbidity and mortality throughout the world (Morgenstern et al., 2010; Palacio and Hart, 2011) . However, developing a targeted therapy or an effective drug to improve ICH outcomes remains a challenge. One potential target is the toll-like receptor (TLR) family. TLRs play an important role in the innate immune system (Avila and Gonzalez-Espinosa, 2011; Garcia-Bonilla et al., 2014) , and TLR4 has been shown to be associated with ICH development (Kong and Le, 2011; Lively and Schlichter, 2012) . It has been reported that elevated TLR4 is associated with poor outcomes of ICH (Fang et al., 2014; Rodriguez-Yanez et al., 2012; Yuan et al., 2015) and that TLR4 inhibition decreases secondary inflammatory damage after ICH (Wang et al., 2013b) . Although it is known that lipopolysaccharide (LPS) is an exogenous ligand of TLR4, to date, no antagonist has shown success in clinic trials. Therefore, the feasibility of using TLR4 as a drug target for ICH needs further study.
In the brain's initial immune response of defense against ICH injury, microglia are rapidly activated and accumulate in the lesion site where they recruit other immune cells (Lan et al., 2011; Wang and Dore, 2007) . However, the roles of activated microglia in ICH are still debated. Activated microglia/macrophages exhibit different phenotypes in different microenvironments and provide distinct functions (Boche et al., 2013; Zhang et al., 2016 Abbreviations: DAPI, 4/6-diamidino-2-phenylindole; FBS, fetal bovine serum; HP-b-CD, hydroxypropyl-b-cyclodextrin; ICH, intracerebral hemorrhage; IKK, IjB kinase; IL-1b, interleukin-1b; IL-6, interleukin-6; IjB, Inhibitor of jB; LPS, lipopolysaccharide; MACS, magnetic-activated cell sorting; NO, nitric oxide; siRNA, small interfering RNA; TLR, toll-like receptor; TNF-a, tumor necrosis factor-a.
